• Explore /
  • Poster
  • / Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

Abstract Poster

Authors

null

Nourhan El Ahmar

Brigham and Women's Hospital, Boston, MA

Nourhan El Ahmar , Sayed Matar , Opeyemi Jegede , Varunika Savla , Aseman Bagheri Sheshdeh , Fatme Ghandour , Thomas Denize , Destiny West , Toni K. Choueiri , Paul J. Catalano , David A. Braun , Naomi B. Haas , Hans J. Hammers , Mehmet Asim Bilen , Mark N. Stein , Jeffrey A. Sosman , Catherine J. Wu , David F. McDermott , Michael B. Atkins , Sabina Signoretti

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03117309

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4549)

DOI

10.1200/JCO.2023.41.16_suppl.4549

Abstract #

4549

Poster Bd #

41

Abstract Disclosures

Similar Posters

First Author: Jean-Christophe Pignon

First Author: Miriam Ficial

First Author: Jean-Christophe Pignon

First Author: Nashat Gabrail